Paula Toro
Overview
Explore the profile of Paula Toro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toro P, Bakhshwin A, Zein-Sabatto B, Khaitan N, Duckworth L, Bennett A, et al.
Mod Pathol
. 2024 Dec;
38(4):100692.
PMID: 39709147
The incidence of anal squamous cell carcinoma (SCC) has increased, and treatment has shifted from surgery to chemoradiotherapy (CRT), with salvage abdominoperineal resection being reserved for persistent/recurrent cases. This study...
2.
Li H, Aggarwal A, Toro P, Fu P, Badve S, Cuzick J, et al.
Lancet Digit Health
. 2024 Jul;
6(8):e562-e569.
PMID: 38987116
Background: The density of tumour-infiltrating lymphocytes (TILs) could be prognostic in ductal carcinoma in situ (DCIS). However, manual TIL quantification is time-consuming and suffers from interobserver and intraobserver variability. In...
3.
Corredor G, Bharadwaj S, Pathak T, Viswanathan V, Toro P, Madabhushi A
Clin Breast Cancer
. 2023 Jun;
23(8):800-812.
PMID: 37380569
Breast cancer is one of the most common and deadly cancers worldwide. Approximately, 20% of all breast cancers are characterized as triple negative (TNBC). TNBC typically is associated with a...
4.
Barrera C, Corredor G, Viswanathan V, Ding R, Toro P, Fu P, et al.
NPJ Precis Oncol
. 2023 Jun;
7(1):52.
PMID: 37264091
The tumor immune composition influences prognosis and treatment sensitivity in lung cancer. The presence of effective adaptive immune responses is associated with increased clinical benefit after immune checkpoint blockers. Conversely,...
5.
Chen Y, Li H, Janowczyk A, Toro P, Corredor G, Whitney J, et al.
NPJ Breast Cancer
. 2023 May;
9(1):40.
PMID: 37198173
Prognostic markers currently utilized in clinical practice for estrogen receptor-positive (ER+) and lymph node-negative (LN-) invasive breast cancer (IBC) patients include the Nottingham grading system and Oncotype Dx (ODx). However,...
6.
Chen Y, Zee J, Janowczyk A, Rubin J, Toro P, Lafata K, et al.
Kidney360
. 2023 Apr;
4(5):648-658.
PMID: 37016482
No abstract available.
7.
Dobritoiu F, Baltan A, Chefani A, Billingham K, Chenard M, Vaziri R, et al.
Appl Immunohistochem Mol Morphol
. 2022 Aug;
30(8):549-556.
PMID: 36036647
Atezolizumab in combination with nab-paclitaxel has been introduced for the treatment of locally advanced or recurrent triple negative breast cancer (TNBC). Patient selection relies on the use of immunohistochemistry using...
8.
Wu Y, Koyuncu C, Toro P, Corredor G, Feng Q, Buzzy C, et al.
Oral Oncol
. 2022 Jun;
131:105942.
PMID: 35689952
Objective: Tissue slides from Oral cavity squamous cell carcinoma (OC-SCC), particularly the epithelial regions, hold morphologic features that are both diagnostic and prognostic. Yet, previously developed approaches for automated epithelium...
9.
Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, et al.
NPJ Precis Oncol
. 2022 Jun;
6(1):33.
PMID: 35661148
Despite known histological, biological, and clinical differences between lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), relatively little is known about the spatial differences in their corresponding immune contextures. Our...
10.
Viswanathan V, Toro P, Corredor G, Mukhopadhyay S, Madabhushi A
J Pathol
. 2022 May;
257(4):413-429.
PMID: 35579955
Lung diseases carry a significant burden of morbidity and mortality worldwide. The advent of digital pathology (DP) and an increase in computational power have led to the development of artificial...